Ironwood Pharmaceuticals

IRWD

Market cap $635M

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced the retirement of Chief Medical Officer and Head of Research and Drug Development Dr. Michael Shetzline and the appointment of Dr. Jeffrey Silber as his successor. Dr. Silber will oversee Research and Drug Development, Regulatory Affairs and Medical Affairs reporting.

COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.

Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.

Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.

Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.

AI-fueled earnings growth helped drive Nasdaq to record highs in 2026, despite valuation concerns, macro headwinds, and geopolitical tensions. Nasdaq-100 earnings grew 46% YoY in Q1, led by AI hyperscalers, but contributions broadened beyond big tech. Earnings remain the ultimate driver of long-term equity performance, according to Nasdaq economists, with the index significantly outperforming the S&P 500 over the past two decades.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4th at 11:05 a.m. ET. A live webcast of Ironwood's fireside chat will be accessible through the Investors & Media section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood Pharmaceutic.

Ironwood gains FDA approval to expand Linzess use to children aged two to five years with functional constipation.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.